Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Credit: Amgen. The application is supported by data from the phase 2 DeLLphi-301 trial. Results showed 40% of patients responded to treatment with Imdelltra. The Food and Drug Administration (FDA) has ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant parts ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the second-line setting, contributing to poor patient outcomes. Advances in therapeutic ...

The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...

Overall survival with serplulimab, a novel PD-1 inhibitor being developed in China for extensive-stage small cell lung cancer (ES-SCLC), appears better than that seen with two immune checkpoint ...